Lilly-backed cell therapy biotech nabs new funds; Colorado biotech nets an acquisition

An Eli Lilly-backed cell therapy biotech has secured $50 million in Series A funds to bankroll CAR-NK therapies.

At the helm of the Shanghai-based Neukio Biotherapeutics is a leader with experience in the CAR-T cell therapy market, with Richard Liqun Wang having previously served as chief executive of the Fosun...

Click to view original post

Lilly-backed cell therapy biotech nabs new funds; Colorado biotech nets an acquisition

An Eli Lilly-backed cell therapy biotech has secured $50 million in Series A funds to bankroll CAR-NK therapies.

At the helm of the Shanghai-based Neukio Biotherapeutics is a leader with experience in the CAR-T cell therapy market, with Richard Liqun Wang having previously served as chief executive of the Fosun...

Click to view original post